Primary plasma cell leukaemia:: a report of 18 cases

被引:64
作者
Costello, R
Sainty, D
Bouabdallah, R
Fermand, JP
Delmer, A
Diviné, M
Marolleau, JP
Gastaut, JA
Olive, D
Rousselot, P
Chaïbi, P
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[2] Inst J Paoli I Calmettes, Unite Immunol Tumeurs, F-13009 Marseille, France
[3] Assistance Publ Hop Paris, Club Reflex Hematol, Paris, France
[4] Hop St Louis, Serv Clin Malad Sang, F-75010 Paris, France
关键词
primary plasma cell leukaemia; multiple myeloma;
D O I
10.1016/S0145-2126(00)00102-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary plasma cell leukaemia (P-PCL) is a variant of multiple myeloma (MM) first diagnosed in the leukemic phase, with >2000/mm(3) circulating plasma cells (PCs) and plasmacytosis >20% of the white cell count. We investigated the clinical characteristics, therapy, immunophenotype and prognosis factors of 18 patients. Common features at diagnosis were asthenia (seven patients), renal insufficiency (ten patients), bone pain (seven patients), splenomegaly or hepatomegaly (five patients). Hypercalcemia was present at diagnosis in seven patients and was the most potent poor prognosis factor (P < 0.05). Most patients (16 out of 18) were treated with an anthracyclin containing regiment; complete remission was attained in one patient and partial remission in 11 patients while six patients had no response. The median survival time from diagnosis was 7 months (2-12, 95% confidence interval), but response to treatment had favorable predictive value (P < 0.05). The PCs were usually positive for mature B-cell markers (PCA-1, CD38). They expressed integrins which may increase their binding to endothelial cells and thus participate in PCL physiopathology by favoring plasmocyte extramedullary spread. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:103 / 107
页数:5
相关论文
共 15 条
[1]   PLASMA-CELL LEUKEMIA RELAPSING IN THE DERMIS [J].
BAREFORD, D ;
PAMPHILON, DH ;
BARNARD, DL .
ACTA HAEMATOLOGICA, 1984, 71 (05) :359-359
[2]  
BERNASCONI C, 1989, EUR J HAEMATOL, V43, P76
[3]  
Costello R, 1996, HEMATOLOGIE, V2, P296
[4]   PRIMARY PLASMA-CELL LEUKEMIA [J].
DIMOPOULOS, MA ;
PALUMBO, A ;
DELASALLE, KB ;
ALEXANIAN, R .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (04) :754-759
[5]   Primary plasma cell leukemia:: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics [J].
García-Sanz, R ;
Orfao, A ;
González, M ;
Tabernero, MD ;
Bladé, J ;
Moro, MJ ;
Fernández-Calvo, J ;
Sanz, MA ;
Pérez-Simón, JA ;
Rasillo, A ;
San Miguel, JF .
BLOOD, 1999, 93 (03) :1032-1037
[6]   Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature [J].
Hovenga, S ;
deWolf, JTM ;
Klip, H ;
Vellenga, E .
BONE MARROW TRANSPLANTATION, 1997, 20 (10) :901-904
[7]   PLASMA-CELL LEUKEMIA - REPORT ON 17 CASES [J].
KYLE, RA ;
MALDONADO, JE ;
BAYRD, ED .
ARCHIVES OF INTERNAL MEDICINE, 1974, 133 (05) :813-817
[8]  
LINDEN MD, 1989, CANCER, V63, P859, DOI 10.1002/1097-0142(19890301)63:5<859::AID-CNCR2820630511>3.0.CO
[9]  
2-B
[10]  
MCELWAIN TJ, 1983, LANCET, V2, P822